Journal of Endocrinological Investigation

, Volume 22, Issue 9, pp 736–737 | Cite as

Receptor imaging in the diagnosis and treatment of pituitary tumors

  • A. Colao
  • S. Lastoria
  • G. Lombardi
  • D. J. Kwekkeboom
  • W. W. de Herder
  • E. P. Krenning
Letter to the Editor


Octreotide Pituitary Adenoma Acromegaly Dopamine Agonist Pituitary Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Lamberts S.W.J., Krenning E.P., Reubi J.C. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr. Rev. 1990, 12: 450.CrossRefGoogle Scholar
  2. 2.
    Kwekkeboom D.J., de Herder W.W., Krenning E.P. Receptor imaging and treatment of pituitary tumors. J. Endocrinol. Invest. 1999, 22: 80.PubMedGoogle Scholar
  3. 3.
    Lamberts S.W.J., Uitterlinden P., Schuijff P.C., Klijn J.G. Therapy of acromegaly with sandostatin: the predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustement and the definition of a biochemical “cure”. Clin. Endocrinol. (Oxf.) 1988, 29: 411.CrossRefGoogle Scholar
  4. 4.
    Colao A., Ferone D., Lastoria S., Marzullo P., Cerbone G., Di Sarno A., Longobardi S., Merola B., Salvatore M., Lombardi G. Prediction of efficacy of octreotide therapy in patients with acromegaly. J. Clin. Endocrinol. Metab. 1996, 81: 2356.PubMedGoogle Scholar
  5. 5.
    van Royen E.A., Verhoeff N.P.L.G., Meylaerts S.A.G., Miedema A.R. Indium-111-DTPA-octreotide uptake measured in normal and abnormal pituitary glands. J. Nucl. Med. 1996, 37: 1449.PubMedGoogle Scholar
  6. 6.
    Plöckinger U., Bäder M., Hopfenmüller H., Saeger W., Quabbe H-J. Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume and hormone-response to octreotide therapy and do not correlate with tumor histology. Eur. J. Endocrinol. 1997, 136: 369.PubMedCrossRefGoogle Scholar
  7. 7.
    Colao A., Lastoria S., Ferone D., Varrella P., Marzullo P., Pivonello R., Cerbone G., Acampa W., Salvatore M., Lombardi G. Pituitary uptake of 111In-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas. J. Endocrinol. Invest. 1999, 22: 176.PubMedCrossRefGoogle Scholar
  8. 8.
    Bevan J.S., Webster J., Burke C.W., Scanlon M.F. Dopamine agonists and pituitary tumor shrinkage. Endocr. Rev. 1992, 13: 220.PubMedCrossRefGoogle Scholar
  9. 9.
    de Herder W.W., Reijs A.E.M., Kwekkeboom D.J. In vivo imaging of pituitary tumors using a radiolabeled dopamine D2 receptor radioligand. Clin. Endocrinol. (Oxf.) 1996, 45: 755.CrossRefGoogle Scholar
  10. 10.
    Scillitani A., Dicembrino F., Di Fazio P., Vettori P.P., D’Angelo V., Scarabino T., Liuzzi A. In vivo visualization of pituitary dopaminergic receptors by iodine-123 methoxibenzamide (IBZM) correlates with sensitivity to dopamine agonists in two patients with macroprolactinomas. J. Clin. Endocrinol. Metab. 1995, 80: 2523.PubMedGoogle Scholar
  11. 11.
    Verhoeff N.P., Bemelman FJ., Wiersinga W.M., van Royen E.A. Imaging of dopamine D2 and somatostatin receptors in vivo using single-photon emission tomography in a patient with TSH/PRL-producing pituitary macroadenoma. Eur. J. Nucl. Med. 1993, 20: 555.PubMedGoogle Scholar
  12. 12.
    Ferone D., Lastoria S., Colao A., Varrella P., Cerbone G., Acampa W., Merola B., Salvatore M., Lombardi G. Correlation of scintigraphic results using 123I-Methoxibenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas. J. Clin. Endocrinol. Metab. 1998, 83: 248.PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 1999

Authors and Affiliations

  • A. Colao
    • 1
  • S. Lastoria
    • 2
  • G. Lombardi
    • 1
  • D. J. Kwekkeboom
    • 3
  • W. W. de Herder
    • 3
  • E. P. Krenning
    • 3
  1. 1.Department of Molecular and Clinical Endocrinology and Oncology“Federico II” University of NaplesNaplesItaly
  2. 2.Department of Nuclear MedicineNational Cancer, Institute of NaplesItaly
  3. 3.Dept. Nuclear MedicineUniversity Hospital RotterdamRotterdamthe Netherlands

Personalised recommendations